US Vaccine to Benefit India? - Trump makes Important Announcement on Launch date!

According to the latest media reports, the Trump administration is considering fast- tracking an experimental COVID19 Vaccine which is being developed by AstraZeneca Plc and Oxford University for using it in United States. According to Financial Times’ report, the vaccine is likely to be used ahead of November 3 elections. 

The Food and Drug Administration (DFA) is considering to award “emergency use authorization” by October to the potential vaccine which is being developed by Oxford and licensed by Astra Zeneca.

However, Astra Zeneca has dismissed claims that the vaccine is being awarded “emergency use authorization”.

"AstraZeneca has not discussed emergency use authorization with the U.S. government and it would be premature to speculate on that possibility," a spokeswoman for AstraZeneca said in a statement.

The company told media that phase 2 and phase 3 trials for the vaccine are ongoing in UK and other parts of the world. 

“Mark Meadows, White House chief of staff, and Steven Mnuchin, Treasury secretary, told top Democrats that the administration was considering fast-tracking a vaccine in a July 30 meeting with Nancy Pelosi, the speaker of the House of Representatives, FT said, citing a person briefed on the meeting,” Livemint reported.

The Serum Institute of India is already working in partnership with Pfizer, a pharma company which is developing a coronavirus vaccine candidate in America. If AstraZeneca’s vaccine candidate gets fast- tracked by the US govt., there is a possibility that SII or some other company might work in partnership with AstraZeneca in order to manufacture the US coronavirus vaccine in India.